Medexus Pharmaceuticals (MDP) investor relations material

Company overview and mission

• Focused on rare disease orphan drugs with significant impact on patient outcomes.

• Operates in the US and Canada with about $100M in revenue and 15 marketed products.

• Management holds significant ownership and emphasizes commercial execution over drug development.

• Business model centers on acquiring and licensing late-stage or registered drugs for commercialization.

• Organic growth and portfolio expansion are driven by business development, with minimal R&D risk.

Key products and growth catalysts

• Grafapix (triosulfan) recently launched, expected to more than double revenue and improve gross margin.

• Grafapix targets allogeneic stem cell transplantation, showing strong clinical and commercial uptake.

• Orphan drug exclusivity for Grafapix provides seven years of market protection.

• Other key products include Xinity for hemophilia B and Risuvo, both holding strong market shares.

• Regulatory and reimbursement milestones, such as MTAP approval, enhance product growth potential.

Financial performance and outlook

• Revenue growth plateaued during Grafapix registration but is expected to accelerate significantly.

• Recent quarters show positive EBITDA, with a rebound after initial launch costs for Grafapix.

• Company trades at less than 1x revenue and 4.4x adjusted EBITDA, seen as undervalued.

• Balance sheet is strong with low net debt and 32M shares outstanding.

• Vision to exceed $500M in revenue, leveraging cash flow from Grafapix to fund further acquisitions.